Mastopon-Treat New (Progesterone)

Progesterone acts on the reproductive hormonal pathway and is employed in several obstetric and gynecologic contexts.

• Luteal phase support: enhances endometrial receptivity during assisted reproductive technology cycles.
• Prevention of preterm birth: reduces the risk of early delivery in women with a short cervix or a history of preterm labor.
• Endometrial preparation: facilitates adequate endometrial thickness for embryo implantation or hormone replacement protocols.

• Progesterone binds intracellular progesterone receptors, forming a hormone‑receptor complex that regulates gene transcription. This modulation influences the menstrual cycle, promotes secretory transformation of the endometrium, supports the luteal phase, and contributes to cervical stability, thereby affecting fertility and pregnancy maintenance.

Progesterone administered vaginally may be associated with a range of adverse reactions.

Common Side Effects

• Vaginal irritation or itching: mild discomfort at the application site.
• Increased vaginal discharge: watery or milky secretion.
• Abdominal cramps or pelvic discomfort.
• Breast tenderness or swelling.
• Headache: mild to moderate intensity.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Allergic reaction: rash, hives, or swelling of face and throat.
• Severe abdominal pain: may indicate underlying complications.
• Pulmonary embolism: rare but potentially life‑threatening clotting event.
• Hyperglycemia: elevated blood glucose in susceptible individuals.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.

When prescribing or dispensing vaginal progesterone, consider the following safety measures.

• Contraindications: avoid use in patients with known hypersensitivity to progesterone or its excipients.
• Thromboembolic risk: use with caution in individuals with a history of clotting disorders.
• Hormone‑sensitive cancers: assess risk before initiating therapy in patients with breast or endometrial cancer.
• Liver function: monitor hepatic parameters in patients with pre‑existing liver disease.
• Pregnancy monitoring: ensure appropriate obstetric follow‑up during use.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Progesterone may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase progesterone levels.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce progesterone efficacy.
• Hormonal contraceptives: potential additive hormonal effects.
• Antiepileptic drugs: may alter hormone metabolism.
• Antifungal azoles (e.g., fluconazole): possible modest increase in progesterone exposure.